Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes
Access StatusFull text of the requested work is not available in DASH at this time ("dark deposit"). For more information on dark deposits, see our FAQ.
Matlin, Olga S.
MetadataShow full item record
CitationGagne, Joshua J., Niteesh K. Choudhry, Aaron S. Kesselheim, Jennifer M. Polinski, David Hutchins, Olga S. Matlin, Troyen A. Brennan, Jerry Avorn, and William H. Shrank. 2014. “Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes.” Annals of Internal Medicine 161 (6) (September 16): 400. doi:10.7326/m13-2942.
AbstractBackground: Statins are effective in preventing cardiovascular events, but patients do not fully adhere to them.
Objective: To determine whether patients are more adherent to generic statins versus brand-name statins (lovastatin, pravastatin, or simvastatin) and whether greater adherence improves health outcomes.
Design: Observational, propensity score–matched, new-user cohort study.
Setting: Linked electronic data from medical and pharmacy claims.
Participants: Medicare beneficiaries aged 65 years or older with prescription drug coverage between 2006 and 2008.
Intervention: Initiation of a generic or brand-name statin.
Measurements: Adherence to statin therapy (measured as the proportion of days covered [PDC] up to 1 year) and a composite outcome comprising hospitalization for an acute coronary syndrome or stroke and all-cause mortality. Hazard ratios (HRs) and absolute rate differences were estimated.
Results: A total of 90 111 patients who initiated a statin during the study was identified; 83 731 (93%) initiated a generic drug, and 6380 (7%) initiated a brand-name drug. The mean age of patients was 75.6 years, and most (61%) were female. The average PDC was 77% for patients in the generic group and 71% for those in the brand-name group (P < 0.001). An 8% reduction in the rate of the clinical outcome was observed among patients in the generic group versus those in the brand-name group (HR, 0.92 [95% CI, 0.86 to 0.99]). The absolute difference was −1.53 events per 100 person-years (CI, −2.69 to −0.19 events per 100 person-years).
Limitation: Results may not be generalizable to other populations with different incomes or drug benefit structures.
Conclusion: Compared with those initiating brand-name statins, patients initiating generic statins were more likely to adhere and had a lower rate of a composite clinical outcome.
Primary Funding Source: Teva Pharmaceuticals.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:33177339
- HMS Scholarly Articles